The document summarizes a market research report from Global Markets Direct titled "Refractory Multiple Myeloma - Pipeline Review, H2 2012". The report provides an overview of the therapeutic pipeline for refractory multiple myeloma, including late-stage and discontinued projects. It reviews key players and their development of treatments, which are organized by stage of development. Tables of contents and figures are also included.

1. Aarkstore.com announces, The Latest market research report is available in
its vast collection:
Refractory Multiple Myeloma – Pipeline Review, H2 2012
http://www.aarkstore.com/reports/Refractory-Multiple-Myeloma-Pipeline-
Review-H2-2012-220603.html
RSS link of Global Markets Direct
http://www.aarkstore.com/feeds/Global-Markets-Direct.xml
Summary
Global Markets Direct’s, Refractory Multiple Myeloma - Pipeline Review, H2 2012,
provides an overview of the Refractory Multiple Myeloma therapeutic pipeline. This
report provides information on the therapeutic development for Refractory Multiple
Myeloma, complete with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the therapeutic
development for Refractory Multiple Myeloma. Refractory Multiple Myeloma -
Pipeline Review, H2 2012 is built using data and information sourced from Global
Markets Direct’s proprietary databases, Company/University websites, SEC filings,
investor presentations and featured press releases from company/university sites
and industry-specific third party sources, put together by Global Markets Direct’s
team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Refractory Multiple Myeloma.
- A review of the Refractory Multiple Myeloma products under development by

2. companies and universities/research institutes based on information derived from
company and industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined
therapeutics.
- Coverage of the Refractory Multiple Myeloma pipeline on the basis of route of
administration and molecule type.
Table of contents:
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Refractory Multiple Myeloma Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Refractory Multiple Myeloma 12
Refractory Multiple Myeloma Therapeutics under Development by Companies 14
Refractory Multiple Myeloma Therapeutics under Investigation by
Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Refractory Multiple Myeloma Therapeutics – Products under Development by
Companies 21
Refractory Multiple Myeloma Therapeutics – Products under Investigation by
Universities/Institutes 22
Companies Involved in Refractory Multiple Myeloma Therapeutics Development 23
Bristol-Myers Squibb Company 23
Abbott Laboratories 24
Eli Lilly and Company 25
Merck & Co., Inc. 26
Piramal Healthcare Limited 27

3. Millennium Pharmaceuticals, Inc. 28
Cephalon, Inc. 29
ImmunoGen, Inc. 30
Pfizer Inc. 31
Celgene Corporation 32
Onyx Pharmaceuticals, Inc. 33
List of Figures
List of Tables are also include.
For more related Reports Plz follow The link:
Pipeline Review, H2 2012
http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H2
2012&PubId=&pagenum=1
Cholangiocellular Hepatoma – Pipeline Review, H2 2012
Hormone Refractory Breast Cancer – Pipeline Review, H2 2012
Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2012
Refractory Multiple Myeloma – Pipeline Review, H2 2012
Epithelial Ovarian Cancer – Pipeline Review, H2 2012
Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H2 2012

4. B-Cell Leukemia – Pipeline Review, H2 2012
Malignant Neoplasms – Pipeline Review, H2 2012
Recurrent Malignant Glioma – Pipeline Review, H2 2012
Endobronchial Cancer – Pipeline Review, H2 2012
Leiomyosarcoma – Pipeline Review, H2 2012
Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2012
Esophageal Tumor – Pipeline Review, H2 2012
Malignant Pleural Mesothelioma – Pipeline Review, H2 2012
Search More Reports Related to This Category :
Pharmaceuticals and Healthcare
http://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals and
Healthcare&PubId=&pagenum=1
You can also request for sample page of above mention reports on
sample@aarkstore.com
For More details Plz do contact :
Aarkstore Enterprise
Lavanya

5. Phone:08149852585
Email: enquiry@aarkstore.com